Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.
about
Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Progression-free survival of f ...... tastatic renal cell carcinoma.
@en
type
label
Progression-free survival of f ...... tastatic renal cell carcinoma.
@en
prefLabel
Progression-free survival of f ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P356
P1476
Progression-free survival of f ...... tastatic renal cell carcinoma.
@en
P2093
Kenichi Taguchi
Motonobu Nakamura
Mototsugu Shimokawa
Nobuki Furubayashi
Shuhei Kusano
Takahito Negishi
Takuya Yamashita
P2860
P304
P356
10.3892/MCO.2017.1320
P577
2017-07-13T00:00:00Z